NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Alder BioPharmaceuticals, Inc. (ALDR) on behalf of Alder shareholders concerning the proposed merger with H. Lundbeck A/S.
Click here to participate in the action.
Pursuant to the proposed transaction, announced on September 16, 2019 and valued at up to $1.95 billion, Alder shareholders will receive $18 in cash and a non-tradeable Contingent Value Right for each share of Alder common stock owned. The Contingent Value Right entitles Alder shareholders to an additional $2 in cash for each share of Alder common stock owned pending the approval of eptinezumab by the European Medicines Agency. The investigation focuses on whether Alder and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Alder shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at email@example.com, or by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Alder please go to https://bespc.com/aldr/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:http://www.prnewswire.com/news-releases/bragar-eagel--squire-pc-is-investigating-the-board-of-directors-of-alder-biopharmaceuticals-inc-nasdaq-aldr-on-behalf-of-alder-shareholders-and-encourages-alder-investors-to-contact-the-firm-300918881.html